PLERIXAFOR CAN PREDICTABLY MOBILIZE HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE

被引:0
|
作者
Tarantolo, S. R. [1 ]
McSweeney, P. A. [2 ]
Micallef, I. N. M. [3 ]
Klein, L. M. [4 ]
Calandra, G. [5 ]
Huebner, D. [5 ]
机构
[1] Nebraske Methodist Hosp, Omaha, NE USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Mayo Clin, Rochester, MN USA
[4] Advocate Lutheran Gen Hosp, Niles, IL USA
[5] Genzyme Corp, Cambridge, MA USA
关键词
D O I
10.1016/j.bbmt.2008.12.113
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
91
引用
收藏
页码:37 / 37
页数:1
相关论文
共 50 条
  • [31] Nonmyeloablative allogeneic stem transplantation in patients with previously treated multiple myeloma
    Cudillo, L
    Picardi, A
    Dentamaro, T
    Postorino, M
    Cupelli, L
    Adorno, G
    Caravita, T
    Tamburini, A
    Lasorella, R
    Cox, C
    de Fabritiis, P
    Amadori, S
    BONE MARROW TRANSPLANTATION, 2002, 29 : S158 - S158
  • [32] Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma
    Ri, Masaki
    Matsue, Kosei
    Sunami, Kazutaka
    Shimazaki, Chihiro
    Hayashi, Akio
    Sunaga, Yoshinori
    Sasaki, Toru
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (04) : 562 - 572
  • [33] Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor
    Taubert, Isabel
    Saffrich, Rainer
    Zepeda-Moreno, Abraham
    Hellwig, Isabelle
    Eckstein, Volker
    Bruckner, Thomas
    Ho, Anthony D.
    Wuchter, Patrick
    CYTOTHERAPY, 2011, 13 (04) : 459 - 466
  • [34] Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma
    Masaki Ri
    Kosei Matsue
    Kazutaka Sunami
    Chihiro Shimazaki
    Akio Hayashi
    Yoshinori Sunaga
    Toru Sasaki
    Kenshi Suzuki
    International Journal of Hematology, 2017, 106 : 562 - 572
  • [35] Effective Primary Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor and Plerixafor in Lenalidomide-Treated Patients with Multiple Myeloma.
    Anwer, Faiz
    Green, Myke R.
    Yeager, Andrew M.
    BLOOD, 2010, 116 (21) : 927 - 927
  • [36] Hematopoietic Progenitor Cell (HPC) Collection Is Feasible in Previously Transplanted Multiple Myeloma Patients and Plerixafor Improves Collection
    Papanikolaou, Xenofon
    Tyler, Lisa
    Barlogie, Bart
    Cottler-Fox, Michele
    BLOOD, 2012, 120 (21)
  • [37] Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide
    Oka, Satoko
    Ono, Kazuo
    Nohgawa, Masaharu
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (06) : 914 - 917
  • [38] Vasculogenesis in patients with multiple myeloma through hematopoietic stem cells
    Ria, R
    Roccaro, AM
    Cirulli, T
    Di Pietro, G
    Falzetti, F
    Ostini, RI
    Zei, T
    Tabilio, A
    Vacca, A
    Dammacco, F
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 108 - 108
  • [39] Plerixafor Salvages Autologous Stem Cell Mobilisation Procedures in Myeloma Patients Previously Treated with Lenalidomide or Autologous HSCT: Cost-effectiveness of Upfront use should be Explored
    Miller, Paul
    Baker, Janet
    Magsipoc, Crischi
    Brennan, Joy
    Mulligan, Maria
    Wells, Janet
    McDonald, Helen
    Boyd, Kevin
    Kaiser, Martin
    Ethell, Mark
    Potter, Mike
    Easdale, Sandra
    Anthias, Chloe
    Nicholson, Emma
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 695 - 696
  • [40] Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients
    Kaya, Sureyya Yigit
    Mutlu, Yasa Gul
    Yucel, Orhan Kemal
    Ozen, Ilknur Nizam
    Atas, Unal
    Melek, Elif
    Maral, Senem
    Karakus, Volkan
    Kaynar, Leylagul
    Sevindik, Omuer Gokmen
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025, 41 (01) : 38 - 42